Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Kengreal Generic Name & Formulations
Legal Class
Rx
General Description
Cangrelor 50mg/vial; lyophilized pwd for IV inj after reconstitution and dilution; contains mannitol, sorbitol.
Pharmacological Class
P2Y12 platelet inhibitor (ATP analog).
How Supplied
Single-use vial (10mL)—1, 10
Manufacturer
Generic Availability
NO
Kengreal Indications
Indications
As adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
Kengreal Dosage and Administration
Adult
Initially 30mcg/kg IV bolus prior to PCI, followed immediately by 4mcg/kg/min IV infusion; continue infusion for ≥2hrs or for duration of PCI, whichever is longer. Transitioning to oral P2Y12 therapy: see full labeling.
Children
Not established.
Kengreal Contraindications
Contraindications
Significant active bleeding.
Kengreal Boxed Warnings
Not Applicable
Kengreal Warnings/Precautions
Warnings/Precautions
Increased risk of bleeding. Discontinue 1hr prior to labor, delivery or neuraxial blockade. Pregnancy. Nursing mothers.
Kengreal Pharmacokinetics
See Literature
Kengreal Interactions
Interactions
Administer clopidogrel or prasugrel after infusion is discontinued.
Kengreal Adverse Reactions
Adverse Reactions
Bleeding, renal impairment, dyspnea, hypersensitivity reactions.
Kengreal Clinical Trials
See Literature
Kengreal Note
Not Applicable
Kengreal Patient Counseling
See Literature
Images
